Introduction: The objective of this work was to assess the factors identified in the Global Adherence Project (GAP) in disease-modifying therapy (DMT) in patients with multiple sclerosis (MS) and to propose measures directed at improving adherence. It was proposed to prepare questionnaires to detect patients at risk of non-adherence before and during the follow-up. Methods: Two meetings were held by Spanish researchers involved in the GAP project. Factors associated with non-adherence were grouped in therapy-, patient-, disease- and health care professional-related factors. Four working groups were created. Each group studied one individual, factor, taking into account the stages of diagnosis, management and administering treatment, follow-...
Danny Decoo,1 Mathieu Vokaer2 1Department of Neurology and Neurorehab, AZ Alma, Sijsele, Belgium; 2...
textabstractBackground: Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of t...
Journal Article; Research Support, Non-U.S. Gov't;BACKGROUND Adherence to interferon β-1b (INFβ-1b)...
Resumen: Introducción: El objetivo de este trabajo fue evaluar los factores, identificados en el es...
Ramón Morillo Verdugo,1 Esther Ramírez Herráiz,2 Raquel Fernández-Del Ol...
Background: In this article we report adherence data from the first 2 years in a subset of patients ...
Aleksandra Kołtuniuk, Joanna Rosińczuk Department of Nervous System Diseases, Faculty of Healt...
Introduction: Non-adherence to disease-modifying therapies (DMTs) in multiple sclerosis may be assoc...
Background and Aims: In multiple sclerosis (MS), non-adherence/non-persistence is related to subopti...
Introduction. Multiple sclerosis is an inflammatory demyelinating disease of the central nervous sys...
Background: Adherence to interferon b-1b (INFb-1b) therapy is essential to maximize the beneficial e...
Adherence to disease-modifying treatments is essential in order to maximize the beneficial effects o...
Background: Adherence to interferon b-1b (INFb-1b) therapy is essential to maximize the beneficial e...
Adherence to interferon β-1b (INFβ-1b) therapy is essential to maximize the beneficial effects of tr...
Adherence to interferon β-1b (INFβ-1b) therapy is essential to maximize the beneficial effects of tr...
Danny Decoo,1 Mathieu Vokaer2 1Department of Neurology and Neurorehab, AZ Alma, Sijsele, Belgium; 2...
textabstractBackground: Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of t...
Journal Article; Research Support, Non-U.S. Gov't;BACKGROUND Adherence to interferon β-1b (INFβ-1b)...
Resumen: Introducción: El objetivo de este trabajo fue evaluar los factores, identificados en el es...
Ramón Morillo Verdugo,1 Esther Ramírez Herráiz,2 Raquel Fernández-Del Ol...
Background: In this article we report adherence data from the first 2 years in a subset of patients ...
Aleksandra Kołtuniuk, Joanna Rosińczuk Department of Nervous System Diseases, Faculty of Healt...
Introduction: Non-adherence to disease-modifying therapies (DMTs) in multiple sclerosis may be assoc...
Background and Aims: In multiple sclerosis (MS), non-adherence/non-persistence is related to subopti...
Introduction. Multiple sclerosis is an inflammatory demyelinating disease of the central nervous sys...
Background: Adherence to interferon b-1b (INFb-1b) therapy is essential to maximize the beneficial e...
Adherence to disease-modifying treatments is essential in order to maximize the beneficial effects o...
Background: Adherence to interferon b-1b (INFb-1b) therapy is essential to maximize the beneficial e...
Adherence to interferon β-1b (INFβ-1b) therapy is essential to maximize the beneficial effects of tr...
Adherence to interferon β-1b (INFβ-1b) therapy is essential to maximize the beneficial effects of tr...
Danny Decoo,1 Mathieu Vokaer2 1Department of Neurology and Neurorehab, AZ Alma, Sijsele, Belgium; 2...
textabstractBackground: Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of t...
Journal Article; Research Support, Non-U.S. Gov't;BACKGROUND Adherence to interferon β-1b (INFβ-1b)...